Ignite Creation Date:
2025-12-26 @ 10:56 AM
Ignite Modification Date:
2025-12-31 @ 12:00 PM
Study NCT ID:
NCT01426308
Status:
COMPLETED
Last Update Posted:
2016-04-28
First Post:
2011-08-29
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Method Comparison and Clinical Specificity Study: Evaluation of the Infinium HD Cytogenetic Abnormality Test
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}}, 'protocolSection': {'designModule': {'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'RETROSPECTIVE', 'observationalModel': 'CASE_ONLY'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 900}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2011-08'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2011-09', 'completionDateStruct': {'date': '2011-11', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2016-04-26', 'studyFirstSubmitDate': '2011-08-29', 'studyFirstSubmitQcDate': '2011-08-30', 'lastUpdatePostDateStruct': {'date': '2016-04-28', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2011-08-31', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2011-11', 'type': 'ACTUAL'}}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'conditions': ['Post-natal Cytogenetics']}, 'descriptionModule': {'briefSummary': 'The study will determine the performance of the Infinium HD Test.\n\n* The primary objective of the study is to assess the performance of the Infinium HD Test using banked DNA samples extracted from whole blood patient samples derived from the intended use population.\n* The secondary objective of the study is to determine the background number of chromosomal abnormalities per person in the general population based on the resolution of the Infinium HD Test.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT'], 'minimumAge': '1 Minute', 'samplingMethod': 'PROBABILITY_SAMPLE', 'studyPopulation': 'Leftover, de-identified DNA extracted from EDTA or heparin anticoagulated whole blood samples.', 'healthyVolunteers': True, 'eligibilityCriteria': 'Method Comparison - Sample Inclusion Criteria\n\nThe following are criteria for inclusion of extracted genomic DNA samples in the method comparison sample pool:\n\n1. Sample is from a patient referred for post-natal cytogenetic testing.\n2. Sample gender is known.\n3. Sample quantity available for testing is ≥ 1 microgram of genomic DNA at a concentration of 60-80 nanograms per microliter (60-80ng/µl).\n4. Sample is extracted genomic DNA from EDTA or heparin-anticoagulated whole blood.\n5. Sample has been stored at 2 to 8°C or -15 to -25°C for no greater than three years from the date of extraction.\n6. Sample has been tested by a reference method. Acceptable reference methods include karyotype, FISH, qPCR, MLPA, and methylation analysis.\n\nMethod Comparison - Sample Exclusion Criteria\n\n1. Sample is from a patient not referred for post-natal cytogenetic testing.\n2. Sample is from a patient referred for cytogenetic oncology testing.\n3. Sample quantity \\< 1 microgram of genomic DNA or less than 60 nanograms per microliter (60ng/µl).\n4. Sample was improperly stored or was extracted from a sample that was improperly stored.\n5. Sample was tested by an Illumina array during standard of care testing.\n\nClinical Specificity - Sample Inclusion Criteria\n\nThe following are criteria for inclusion of extracted genomic DNA samples in the clinical specificity sample pool:\n\n1. Sample gender is known.\n2. Sample is from a patient not referred for post-natal cytogenetic testing.\n3. Sample quantity available for testing is ≥ 1 microgram of genomic DNA at a concentration of at least 60-80 nanograms per microliter (60-80ng/µl).\n4. Sample is extracted genomic DNA from EDTA or heparin-anticoagulated whole blood.\n5. Sample has been stored at 2 to 8°C or -15 to -25°C for no greater than three years from the date of extraction.\n\nClinical Specificity - Sample Exclusion Criteria\n\n1. Sample is from a patient referred for post-natal cytogenetic testing.\n2. Sample quantity \\< 1 microgram of genomic DNA or less than 60 nanograms per microliter (60ng/µl).\n3. Sample was improperly stored or was extracted from a sample that was improperly stored.'}, 'identificationModule': {'nctId': 'NCT01426308', 'briefTitle': 'Method Comparison and Clinical Specificity Study: Evaluation of the Infinium HD Cytogenetic Abnormality Test', 'organization': {'class': 'INDUSTRY', 'fullName': 'Illumina, Inc.'}, 'officialTitle': 'Method Comparison and Clinical Specificity Study: Evaluation of the Infinium HD Cytogenetic Abnormality Test', 'orgStudyIdInfo': {'id': 'Cyto-001'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Method Comparison Group', 'description': 'The method comparison group will consist of de-identified, leftover DNA samples from patients referred for post-natal cytogenetic testing.'}, {'label': 'Clinical Specificity Group', 'description': 'The clinical specificity group will consist of de-identified, leftover DNA samples from non-phenotypic patients, or patients not referred for post-natal cytogenetic testing.'}]}, 'contactsLocationsModule': {'locations': [{'zip': '29403', 'city': 'Charleston', 'state': 'South Carolina', 'country': 'United States', 'facility': 'Medical University of South Carolina', 'geoPoint': {'lat': 32.77632, 'lon': -79.93275}}, {'zip': '77021', 'city': 'Houston', 'state': 'Texas', 'country': 'United States', 'facility': 'Baylor College of Medicine', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '84108', 'city': 'Salt Lake City', 'state': 'Utah', 'country': 'United States', 'facility': 'ARUP Laboratories', 'geoPoint': {'lat': 40.76078, 'lon': -111.89105}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Illumina, Inc.', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}